Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
04 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic strokeData shows behavioral outcomes improvement at one month in model of...
Postpartum hemorrhage cart and medication kit interventions improve response to leading cause of maternal morbidity
25 janv. 2022 12h03 HE
|
The Joint Commission
OAKBROOK TERRACE, Illinois, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity in the United States. Delayed treatment of PPH, including due to...
Intracranial Pressure Monitoring Devices Market Predicted to Garner $1,625.7 Million and Grow at a CAGR of 3.3% from 2019 to 2026 - Absolute Report by Research Dive
29 mars 2021 09h14 HE
|
Research Dive
New York, USA, March 29, 2021 (GLOBE NEWSWIRE) -- As per a Research Dive published report, the global intracranial pressure monitoring devices market valued for $1,256.6 million in 2018 and is...
Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference
02 mars 2020 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020
08 janv. 2020 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference
03 sept. 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
05 août 2019 07h50 HE
|
Arch Therapeutics, Inc.
Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body FRAMINGHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics,...
Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational
30 mai 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05 févr. 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...